Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA of $3,433.5 million, up 9 percent from $3,156.9 million in the same period last year. The company reported flat third-quarter revenues of $3,749.5 million against $3,759.9 million a year earlier, but adjusted earnings per share of $1.99 for the nine months ended September 30 climbed 12 percent from $1.78, signaling margin expansion and cost discipline offsetting top-line pressure.
Third-quarter total net sales of $3,734.7 million declined less than 1 percent on a reported basis from $3,747.5 million, with operational declines of the same magnitude. Greater China drove growth, with nine-month net sales up 19 percent reported and 15 percent on an operational basis to $2,096.5 million from $1,759.6 million, while Developed Markets slipped 1 percent operationally to $6,430.4 million. Brands net sales grew 5 percent reported for the nine months to $7,212.3 million; Generics declined 2 percent reported to $3,778.0 million. The company generated $287 million in new product revenues through nine months and now expects to deliver approximately $450 million for the full year. Free cash flow for the nine months reached $1,491.1 million, up 13 percent from $1,317.8 million. The company returned approximately $717 million to shareholders year to date through repurchases and other capital returns.
What it means
Viatris is managing a revenue plateau by tightening margins and accelerating new product contribution. Adjusted gross margin expanded to 57.2 percent for the nine months from 56.2 percent, and adjusted EBITDA growth of 9 percent on flat operational sales growth suggests the company is extracting more cash from each dollar of revenue. The nine-month adjusted EPS gain of 12 percent against operational revenue growth of 2 percent points to operational leverage from cost actions and higher-margin product mix, not volume expansion.
The open question is whether new product revenue acceleration, from $287 million through nine months to a $450 million full-year run rate, can sustain growth into 2027 or whether it masks underlying softness in the base business. Greater China’s 15 percent operational growth and Developed Markets’ 1 percent decline suggest uneven geographic performance; Europe supply constraints and Emerging Markets pressure persist. The company’s planned acquisition of Pacira BioSciences, expected to close by end of November, is excluded from current guidance and adds a variable to next year’s trajectory.
Watch the company’s full-year 2026 results filing in early 2027 for confirmation that new product revenues sustain the $450 million target and for initial Pacira contribution guidance, which will signal whether the acquisition is positioned as a near-term revenue driver or a longer-term pipeline play.
Source: the company’s 8-K filed 2026-11-05 with the SEC.
For the standing yardsticks on Viatris: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Viatris.
